SR-9009, sold as stenabolic, is a synthetic agonist of the clock-linked nuclear receptors REV-ERB-alpha and REV-ERB-beta.
Amounts reported for SR-9009 are listed under Reported protocols, each with its source and study kind. No amount ladder is inferred from them. This is educational source context, not a protocol or recommendation.
Enter a target amount only from your own reviewed source. The calculator can convert it into concentration, volume and device markings, but it will not infer an amount from product availability or another compound.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No human amount or schedule has been recorded for this compound.
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
What published studies and recent community write-ups report about amounts, timing and course length. 2 preclinical and 2 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Preclinical2 rows | |||||
| Diet-induced obese mice, the founding metabolic studyMale C57BL/6 mice aged 20 weeks, mean weight 41 g, kept 14 weeks on a 60% fat diet, 6 to 10 per group | 100 mg/kg | Twice daily, at the start and midpoint of the light cycle | Intraperitoneal injection | 30 daysNot applicable | Nature (PubMed)2012 |
| Plasma triglycerides fell 12%, total cholesterol 47%, non-esterified fatty acids 23%, glucose 19%, leptin 80% and interleukin-6 72%, with food intake unchanged. The paper states plainly that vehicle-treated controls also lost weight from the stress of handling and twice-daily injection, so the often-quoted 60% greater weight loss is an excess over an already-falling baseline rather than a comparison with untreated animals. This is a milligram-per-kilogram injected rodent dose and does not convert to a human amount. | |||||
| Receptor specificity test in REV-ERB double-knockout cellsMouse embryonic stem cells and hepatocytes with both REV-ERB-alpha and REV-ERB-beta deleted, against double-floxed controls | 10 micromolar, the concentration used in many published studies | Single exposure | In vitro, 2 days for viability and metabolism and 8 hours for transcription | 2 daysNot applicable | Proceedings of the National Academy of Sciences2019 |
| The compound still reduced cell viability, rewired cellular metabolism and changed gene transcription in cells that contained neither of its intended receptors. The authors conclude that its effects cannot be used as a proxy for REV-ERB activity and that investigators using it should be told so. They also point out that the molecule contains a 5-nitrothiophene, a recognised toxicophore. | |||||
| Community-reported2 rows | |||||
| What is actually in products sold online | Label amount matched laboratory analysis in only 18 of 44 products | Not stated | Products bought from internet suppliers and analysed under anti-doping procedures | Not stated | JAMA (PubMed)2017 |
| This JAMA analysis of 44 products marketed as selective androgen receptor modulators found that 39% contained a different unapproved drug, this compound among them, and that the stated amount differed substantially from the measured amount in 59% of products. It is also the reason this molecule is so often mislabelled a SARM: it has no androgen receptor pharmacology at all. | |||||
| Circulating claims checked against primary sources | Oral schedules of 2 or 3 administrations a day, and a half-life of about 4 hours, are the figures usually quoted | Not stated | Described online as oral | Not stated | Community resource2026 |
| This editorial ledger logged 20 claims about the compound and traced 8 of them to no source. Among those: that it is orally active, that it has a four-hour half-life, that it raises endurance by a stated percentage, that it is non-hormonal and needs no recovery protocol, and that human trials exist. Every in vivo study it retrieved used intraperitoneal injection, no pharmacokinetic study of the molecule was located, and a direct query of the trial registry returned zero registrations under any of its names. | |||||
The metabolic result that made this compound famous required two intraperitoneal injections a day for a month, timed to the light cycle, in obese mice. There is no version of that protocol that a person could follow, and no study has tested whether the molecule survives the gut.
A 2013 Nature Medicine study reported that treated mice ran significantly longer in time and distance than vehicle controls, with six animals per group. The 50% figure attached to this compound everywhere online comes from the institute's own press release, not from the paper, whose figure legend gives no percentage, effect size or p value.
There is no first-in-human study, no registered trial, no dose range, no human pharmacokinetics and no safety database. Any schedule written for people is an invention, because nothing in the literature describes what happens when a person takes this compound.
Plus 1 community resource (a dosing guide, forum thread or vendor write-up), reported above but not linked.
SR-9009, sold as stenabolic, is a synthetic agonist of the clock-linked nuclear receptors REV-ERB-alpha and REV-ERB-beta, made at the Scripps Research Institute in 2012 as a laboratory tool. No human trial of it has ever been registered or published, and every result in a living animal came from intraperitoneal injection in rodents, so there is no oral administration study in any species and no measurement of its oral absorption. A 2019 experiment in cells engineered to lack both REV-ERB proteins found that most of its effects persisted, which means those effects cannot be attributed to the receptor it was designed to hit.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
Energy balance, body composition and incretin signaling.
Androgen receptor modulators, myostatin pathways and exercise-mimetic research.
Plasma triglycerides fell 12%, total cholesterol 47%, non-esterified fatty acids 23%, glucose 19%, leptin 80% and interleukin-6 72%, with food intake unchanged. The paper states plainly that vehicle-treated controls.
The compound still reduced cell viability, rewired cellular metabolism and changed gene transcription in cells that contained neither of its intended receptors. The authors conclude that its effects cannot be used as a.
This JAMA analysis of 44 products marketed as selective androgen receptor modulators found that 39% contained a different unapproved drug, this compound among them, and that the stated amount differed substantially.
This editorial ledger logged 20 claims about the compound and traced 8 of them to no source. Among those: that it is orally active, that it has a four-hour half-life, that it raises endurance by a stated percentage.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
2 protocol rows describe animal, cell or toxicology work. Amounts from these rows do not translate to people.
2 rows record what blogs, vendor write-ups or forums describe for SR-9009. None has been verified against primary literature.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
SR9009, SR 9009, Stenabolic, REV-ERB Agonist II, UNII X5DCA09N30, CHEMBL1961796, DrugBank DB14013, DTXSID901045515
MMJJNHOIVCGAAP-UHFFFAOYSA-N
ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate
5 curated references, each with its journal, year and study model, plus 1 community resource reported but not linked.